On behalf of the OncoSec team, we’re thrilled to announce the first patient enrolled in the Phase II Investigator Sponsored Trial led by the University of California, San Francisco (UCSF) to assess the safety and efficacy of the combination of our investigational therapy, ImmunoPulse™ IL-12, and Merck’s approved anti-PD-1 agent, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic melanoma.
We were thrilled to participate in the Nasdaq Opening Bell Ceremony to celebrate our recent listing to The Nasdaq Capital Market. This marks an exciting and significant milestone for our company as we continue to build on our success and advance our technologies to one day benefit patients everywhere.
On May 27th, we proudly announced that our common stock has been listed on The NASDAQ Capital Market. We’re very excited to be following an upward trajectory and expect this milestone will bring several benefits to the company, ranging from appealing to a broader set of investors to increasing the visibility of OncoSec’s capabilities.
On behalf of OncoSec, I want to thank our shareholders for their ongoing support of our mission to develop novel intratumoral immunotherapies to treat cancer. To date, the company has never been stronger in terms of our ImmunoPulse™ technology, advanced clinical pipeline, and collaborations with academic and industry institutions.
Exclusive Q&A with Punit Dhillon, CEO of OncoSec Medical, on Developing Innovative Cancer Treatments
Being cutting-edge by introducing new tech advances is great, but it’s not the only way to go in entrepreneurship. Just ask the 34-year-old Punit Dhillon.
Punit Dhillon launched OncoSec Medical in 2011, leveraging “dead technology” to develop innovative medical treatments that harness the body’s immune system to detect and fight cancer. The revolutionary breakthrough has given hope to cancer patients and helped the company to grow from $20 to $100 million in less than 4 years. In this Q&A, I talked with Punit about his innovation and entrepreneurship in general. Continue reading “Interview with Ivan Widjaya, Noobpreneur.com”
This Tuesday, the OncoSec team will play host to some of the most brilliant minds in immuno-oncology, with our highly anticipated symposium, “An Introspective on Immunotherapy: A Symposium on Intratumoral Therapy.” The event promises to be a notable high point during the week of J.P. Morgan’s annual healthcare conference, a week that has historically attracted the “who’s who” of the healthcare sector.
Last week, sunny San Diego was the site of a big event (no, I don’t mean, Comic Con): the 2014 DNA Vaccine Conference hosted by the International Society of DNA Vaccines (ISDV). I thought I’d take the opportunity to describe some of the “best of conference,” as seen through the completely biased eyes of OncoSec’s CMO and what it means for our mission of furthering intratumoral immunotherapy.
“Let’s talk about the need for combinatorial approaches in oncology therapy – in particular, for immunotherapies.”
On Tumor Immune Evasion
Tumors deploy multiple parallel mechanisms that synergize – meaning that they work together to get more bang for their buck. In this way, tumors are able to subvert the immune response and protect themselves from being eradicated by the immune system. Thus, we need to similarly deploy multiple parallel synergistic mechanisms to re-program the immune response – to re-hijack it from tumors.
It is very rare that you find a patient with a tumor that has a dominant immune checkpoint – where you can simply reverse that one mechanism and see an effect. To put it frankly, we need to move towards combination approaches in immunotherapy. Continue reading “Paging Dr. Pierce: OncoSec CMO Discusses the Need for Combination Therapies”
This past month, OncoSec’s Chief Medical Officer, Dr. Robert Pierce, participated in the 6th Annual Melanoma Research Alliance Scientific Retreat The conference seeks to advance the field of melanoma research, by providing an interactive forum that facilitates data sharing and discussion among key field leaders. This is accomplished through guest participation in a series of collaborative and thought-provoking activities, including panel discussions and notable speaker presentations. Continue reading “OncoSec CMO Participates in 6th Annual Melanoma Research Alliance Scientific Retreat”